Rituximab: A Review of Use in Adult Rheumatology
by Kenina Silvera, 2024 PharmD Candidate, Diane Oddis, BPharm, BCPS, William Krombholz, PharmD, Amy Gorgen, BPharm
"Though rituximab was originally approved for treating non-Hodgkin's lymphoma, its use has expanded to a variety of disease states, including immune-mediated rheumatic diseases. This literature review aims to summarize recommendations for rituximab use in adults with rheumatic diseases that have American College of Rheumatology (ACR) or European Alliance of Associations for Rheumatology (EULAR) guidelines available. Additionally, this review aims to briefly summarize evidence and dosing for rituximab in each disease state, as well as the available formulations."
Keywords: Rituximab, Biosimilar Pharmaceuticals, Antibodies, Antineutrophil Cytoplasmic, Rheumatoid Factor, Microscopic Polyangiitis, Autoantibodies, Cytokines, Felty Syndrome, Synovial Fluid, Cost Savings, Granulomatosis with Polyangiitis, Prevalence, Antineoplastic Agents, Antibodies, Monoclonal, Arthritis, Rheumatoid, Neoplasms, Lupus Erythematosus, Systemic, Lymphoma, Bone Resorption, Insurance Coverage
Download PDF
2023 November/December Table of Contents
"Though rituximab was originally approved for treating non-Hodgkin's lymphoma, its use has expanded to a variety of disease states, including immune-mediated rheumatic diseases. This literature review aims to summarize recommendations for rituximab use in adults with rheumatic diseases that have American College of Rheumatology (ACR) or European Alliance of Associations for Rheumatology (EULAR) guidelines available. Additionally, this review aims to briefly summarize evidence and dosing for rituximab in each disease state, as well as the available formulations."
Keywords: Rituximab, Biosimilar Pharmaceuticals, Antibodies, Antineutrophil Cytoplasmic, Rheumatoid Factor, Microscopic Polyangiitis, Autoantibodies, Cytokines, Felty Syndrome, Synovial Fluid, Cost Savings, Granulomatosis with Polyangiitis, Prevalence, Antineoplastic Agents, Antibodies, Monoclonal, Arthritis, Rheumatoid, Neoplasms, Lupus Erythematosus, Systemic, Lymphoma, Bone Resorption, Insurance Coverage
Download PDF
2023 November/December Table of Contents